Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å evaluere effektiviteten og sikkerheten til QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometason Furoat) versus Salmeterol Xinafoate / Flutikasonpropionat hos barn fra 12 år til under 18 år med astma

9. november 2026 oppdatert av: Novartis Pharmaceuticals

En dobbelt-dummy, dobbeltblind, randomisert, parallellgruppe, aktiv kontrollert studie for å evaluere effektiviteten og sikkerheten til QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasonfuroate) sammenlignet med Salmeterol Xinafoate/Fluticasone Propionate hos barn fra 12 år til barn fra 12 år Over 18 år med astma

The purpose of this study is to evaluate the efficacy and safety of indacaterol acetate / glycopyrronium bromide / mometasone furoate (QVM149) compared to salmeterol xinafoate / fluticasone propionate in children from 12 to less than 18 years of age with asthma with pre-bronchodilator FEV1 ≥ 50 % of the predicted normal value for the participant.

Studieoversikt

Detaljert beskrivelse

This is a double-dummy, double-blind, randomized, active controlled, two-way two-period treatment (12 weeks duration each) cross-over study.

The study duration of 36 weeks includes:

  • a screening period of up to 15 days (rescue medication: short acting β2-agonist (SABA) salbutamol 100 μg or albuterol 90 μg via a Metered-Dose Inhaler (MDI) to use as-needed throughout the study).
  • a run-in period of 14 days (run-in medication: salmeterol xinafoate 50 μg / fluticasone propionate 250μg bid delivered via Girohaler® or equivalent DPI device)
  • two treatment period of 12 weeks each (either QVM149 150/50/160 µg od and placebo to salmeterol xinafoate/fluticasone propionate 50/500 µg bid, or salmeterol xinafoate/fluticasone propionate 50/500 µg bid and placebo to QVM149 150/50/160 µg od, separated by a 3 week washout period (wash-out medication: salmeterol xinafoate/fluticasone propionate 50/250 µg bid)
  • a safety follow up period of 30 days during which the participant will be back on standard of care treatment as appropriate.

Studietype

Intervensjonell

Registrering (Antatt)

188

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

  • Navn: Novartis Pharmaceuticals

Studiesteder

    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2000DIF
        • Rekruttering
        • Novartis Investigative Site
      • Strasbourg, Frankrike, 67091
        • Rekruttering
        • Novartis Investigative Site
      • Bialystok, Polen, 15-698
        • Rekruttering
        • Novartis Investigative Site
      • Krakow, Polen, 31-625
        • Rekruttering
        • Novartis Investigative Site
      • Lublin, Polen, 20-637
        • Rekruttering
        • Novartis Investigative Site
      • Piaseczno, Polen, 05-500
        • Rekruttering
        • Novartis Investigative Site
      • Torun, Polen, 87-100
        • Rekruttering
        • Novartis Investigative Site
    • Poland
      • Tarnów, Poland, Polen, 33-100
        • Rekruttering
        • Novartis Investigative Site
      • Bucharest, Romania, 050159
        • Rekruttering
        • Novartis Investigative Site
      • Banská Bystrica, Slovakia, 974 09
        • Rekruttering
        • Novartis Investigative Site
      • Bratislava, Slovakia, 833 40
        • Rekruttering
        • Novartis Investigative Site
      • Košice, Slovakia, 040 22
        • Rekruttering
        • Novartis Investigative Site
    • Mestska Cast Ruzinov
      • Bratislava, Mestska Cast Ruzinov, Slovakia, 821 08
        • Rekruttering
        • Novartis Investigative Site
      • Seville, Spania, 41013
        • Rekruttering
        • Novartis Investigative Site
    • A Coruna
      • Santiago Compostela, A Coruna, Spania, 15706
        • Rekruttering
        • Novartis Investigative Site
    • Barcelona
      • Sabadell, Barcelona, Spania, 08208
        • Rekruttering
        • Novartis Investigative Site
      • Cape Town, Sør-Afrika, 7531
        • Rekruttering
        • Novartis Investigative Site
      • Pretoria, Sør-Afrika, 0181
        • Rekruttering
        • Novartis Investigative Site
    • Eastern Cape
      • East London, Eastern Cape, Sør-Afrika, 5201
        • Rekruttering
        • Novartis Investigative Site
    • Gauteng
      • Germiston, Gauteng, Sør-Afrika, 1401
        • Rekruttering
        • Novartis Investigative Site
      • Krugersdorp, Gauteng, Sør-Afrika, 1739
        • Rekruttering
        • Novartis Investigative Site
      • Lenasia, Gauteng, Sør-Afrika, 1827
        • Rekruttering
        • Novartis Investigative Site
    • Western Cape
      • Paarl, Western Cape, Sør-Afrika, 7626
        • Rekruttering
        • Novartis Investigative Site
      • Kaohsiung City, Taiwan, 833
        • Rekruttering
        • Novartis Investigative Site
      • Bielefeld, Tyskland, 33617
        • Rekruttering
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Wesel, North Rhine-Westphalia, Tyskland, 46483
        • Rekruttering
        • Novartis Investigative Site
      • Szeged, Ungarn, 6720
        • Rekruttering
        • Novartis Investigative Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

12 år til 17 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion criteria:

  • Male and female adolescent participants aged from ≥ 12 years old to less than 18 years old at screening visit
  • Participants with a documented diagnosis of persistent asthma (according to Global Initiative for Asthma GINA 2024) for a period of at least 1 year prior to screening.
  • Participants who have used medium or high dose ICS with LABA in combination (GINA 2024) for asthma for at least 3 months and at stable doses for at least 1 month prior to screening
  • Participants must be symptomatic / inadequately controlled according to the Investigator's opinion despite treatment with medium or high stable doses of ICS with LABA in combination (GINA 2024) before screening
  • Participants who demonstrate an increase in FEV1 of ≥ 12% within 15 to 30 minutes after administration of 200-400 μg salbutamol/180-360 μg albuterol at run-in visit
  • Pre-bronchodilator FEV1 ≥ 50% of the predicted normal value for the participant according to American Thoracic Society/European Respiratory Society (ATS/ERS) 2019 criteria at both run-in and before randomization

Key Exclusion criteria:

  • Participants who have had a severe asthma attack/exacerbation requiring systemic steroids OR hospitalization (> 24 hours) OR emergency room (ER) visit (≤ 24 hours) within 6 weeks of screening. If participants experience an asthma attack/exacerbation requiring systemic steroids or emergency room visit between screening and end of run-in they may be re-screened 6 weeks after recovery from the exacerbation
  • Participants who have ever required intubation for a severe asthma attack/exacerbation
  • Participants with a history of chronic lung diseases other than asthma, including (but not limited to) sarcoidosis, interstitial lung disease, cystic fibrosis, clinically significant bronchiectasis and active tuberculosis
  • Participants with Type I diabetes or uncontrolled Type II diabetes
  • Participants who have a clinically significant laboratory abnormality as per investigator judgement before the end of run-in
  • Participants with a history of myocardial infarction (this should be confirmed clinically by the Investigator) within the previous 12 months
  • Participants with a history of long QT syndrome or a family history of a first degree relative with sudden cardiac death under the age of 50 years, or participants whose QTc measured at run-in or at baseline (prior to randomization) (Fridericia method) is prolonged (> 450 msec for males and > 460 msec for females) and confirmed by a central assessor or the inability to determine the QT interval corrected by Fridericia's formula (QTcF) interval (these participants should not be re-screened)
  • Female participants of childbearing potential defined as all females physiologically capable of becoming pregnant (e.g. are menstruating) who do not agree to abstinence or, if sexually active, do not agree to the use of contraception as defined in the exclusion criteria
  • Use of long-acting muscarinic antagonist (LAMA) within 3 months prior to screening

Other protocol-defined inclusion/exclusion criteria may apply.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm 1: QVM149 first, then salmeterol xinafoate/fluticasone propionate
  • QVM149 150/50/160 µg od and placebo to salmeterol xinafoate/fluticasone propionate 50/500 μg bid during treatment period 1.
  • Then, after a 3-week washout period, salmeterol xinafoate/fluticasone propionate 50/500 μg bid and placebo to QVM149 150/50/160 µg od during treatment period 2.

QVM149: Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg once daily delivered via Breezhaler®

Salmeterol xinafoate 50 μg / fluticasone propionate 500 μg twice daily delivered via Girohaler®

Placebo to QVM149 150/50/160 µg once daily delivered via Breezhaler®

Placebo to salmeterol xinafoate/fluticasone propionate 50/500 μg twice daily delivered via Girohaler®

Eksperimentell: Arm 2: Salmeterol xinafoate/fluticasone propionate first, then QVM149
  • Salmeterol xinafoate/fluticasone propionate 50/500 μg bid and placebo to QVM149 150/50/160 µg od during treatment period 1.
  • Then, after a 3-week washout period, QVM149 150/50/160 µg od and placebo to salmeterol xinafoate/fluticasone propionate 50/500 μg bid during treatment period 2.

QVM149: Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg once daily delivered via Breezhaler®

Salmeterol xinafoate 50 μg / fluticasone propionate 500 μg twice daily delivered via Girohaler®

Placebo to QVM149 150/50/160 µg once daily delivered via Breezhaler®

Placebo to salmeterol xinafoate/fluticasone propionate 50/500 μg twice daily delivered via Girohaler®

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from Baseline in Trough FEV1
Tidsramme: Baseline, Week 12 of each treatment period.

FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.

Baseline, Week 12 of each treatment period.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from Baseline in Asthma Control Questionnaire (ACQ-5) score
Tidsramme: Baseline, Week 12 of each treatment period

The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. The five questions (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheeze) enquire about the frequency and/or severity of symptoms over the previous week. The response options for all these questions range from zero (no impairment/limitation) to six (total impairment/ limitation) scale. ACQ-5 score range from 0 to 6. Higher scores indicates worsening of condition.

Baseline, Week 12 of each treatment period
Change from Baseline in Pediatric Asthma Quality of Life Questionnaire (PAQLQ) total score
Tidsramme: Baseline, Week 12 of each treatment period

Pediatric Asthma Quality of Life Questionnaire is a 23-item disease specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with 7-point scale (7-not bothered at all, 1-extremely bothered). It consists of 3 domains: symptoms, activity limitation and emotional function. Higher scores indicate less impairment in HRQOL.

The overall PAQLQ score is the mean of all 23 responses and the individual domain scores are the means of the items in those domains.

Baseline, Week 12 of each treatment period
Change from Baseline in average Rescue medication use (daily, daytime, and nighttime)
Tidsramme: Baseline, Week 12 of each treatment period

Rescue medication use over 12 weeks of each treatment period.

Baseline, Week 12 of each treatment period
Number and severity of reported asthma exacerbations
Tidsramme: Baseline, Week 12 of each treatment period

Asthma exacerbations over 12 weeks of each treatment period

Baseline, Week 12 of each treatment period
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: From first dose up to 30 days after last dose (up to 31 weeks)

Number of participants with AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs.

From first dose up to 30 days after last dose (up to 31 weeks)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

4. august 2026

Primær fullføring (Antatt)

30. desember 2028

Studiet fullført (Antatt)

30. januar 2029

Datoer for studieregistrering

Først innsendt

6. mars 2023

Først innsendt som oppfylte QC-kriteriene

18. mars 2023

Først lagt ut (Faktiske)

20. mars 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere